Market Overview

Analysts See 700% Upside In Sorrento Therapeutics After Unsolicited Takeover Bid

Share:
Analysts See 700% Upside In Sorrento Therapeutics After Unsolicited Takeover Bid

Sorrento Therapeutics Inc (NASDAQ: SRNE) shares are on a roller coaster ride after the company turned down an unsolicited, non-binding offer Monday from two biopharma companies to acquire all outstanding stock at $3-$5 per share in cash. 

The actively traded, small-cap biotech's shares were pulling back Tuesday after nearly doubling in the previous session.

Takeout Offer Received And Rejected

The offer rejected by Sorrento represented a roughly 88% to 331% premium to the $1.16 at which the shares closed Friday ahead of the company making the approach public. 

Sorrento said the offer, which was made Nov. 23, signficantly undervalued the company and was not in its best interest, leading the board to reject the proposal. 

Sorrento's Rich Pipeline

Sorrento has one Phase 1 CD38 CART-T asset being developed for multiple myeloma and three other immuno-oncology assets in pre-clinical development.

Its non-opioid pain management portfolio has a commercial product in ZTildo 1.8%, which has been approved for postherpetic neuralgia. ZTildo is in clinical development for additional indications.

The company is also evaluating another pain medication, resiniferatoxin, in clinics for several indications.

The positive stock reaction to the rejection could reflect positive investor sentiment regarding the company's rich and deep pipeline.

Sorrento Analysts See 700% Upside Potential

Even with Monday's gains, the stock is primed for incremental upside, according to sell-side analysts.

The average rating for Sorrento is a Buy and the average price target is $24.50, according to the Yahoo database, with JMP analyst Donald Ellis recently reiterating an Outperform rating and $21 price target. This represents roughly 700% upside on top of Monday's strong gains.

The stock was down 2.41% at $3.04 at the time of publication Tuesday.

Related Links:

The Daily Biotech Pulse: ChemoCentryx Triples On Data Readout, Global Blood Given FDA Nod, Positive Safety Review For Genfit's NASH Drug

CymaBay Halts Study On Lead Clinical Program, Stock Crashes

Posted-In: Biotech M&A News Top Stories Trading Ideas Best of Benzinga

 

Related Articles (SRNE)

View Comments and Join the Discussion!
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

The Unregulated CBD Industry Is A Relic Of The Past

Stocks That Hit 52-Week Lows On Tuesday